Shareholder Alert for Regeneron Pharmaceuticals (REGN) скачать в хорошем качестве

Shareholder Alert for Regeneron Pharmaceuticals (REGN)

Anyone who incurred a loss as a result of this misconduct can join the suit: https://zlk.com/pslra-1/regeneron-pha... A Department of Justice investigation into pharmaceutical manufacturer Regeneron left investors wide-eyed. The stunning allegations caused investors to rapidly sell off their shares and Regeneron’s stock price plunged over nine percent. Some of those investors are now joining a class-action lawsuit against the Company. Regeneron’s leading products are Eylea and Eylea HD, drugs which treat macular degeneration. In the Company’s February twenty twenty-four quarterly financial report, Regeneron reported making one point four billion dollars on the Eylea brand. Some of this money came from billing Medicaid and Medicare for Eylea prescriptions. But, Regeneron’s executives knew the Eylea sales figures were based on fraudulent Medicaid and Medicare billing practices. In April twenty-twenty four, the U.S Department of Justice filed a case against the Company alleging Regeneron regularly overbilled the Government for Regeneron prescriptions. In October, investors learned how much overbilling propped up Regeneron’s bottom line. Quarterly sales for Eylea were thirty million dollars below expectations, due to what the Company called a “lower net selling price.” Investors quickly dumped their shares after learning this news. Some of those investors are now joining the lawsuit.